[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chemotherapy-induced-nausea-and-vomiting-cinv\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chemotherapy-induced-nausea-and-vomiting-cinv":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100648839","phase-2-fosrolapitant-combined-with-palonosetron-to-prevent-trastuzumab-rezetecan-related-cinv-100648839",false,"NCT07726433","Fosrolapitant Combined With Palonosetron to Prevent Trastuzumab Rezetecan Related CINV","A Multicenter, Exploratory Clinical Study of the Efficacy and Safety of Phentolamine and Palonosetron for the Prevention of Nausea and Vomiting Associated With Recom-Trastuzumab Therapy","Inclusion Criteria:\n\n1. Sign a written informed consent form and voluntarily enroll in this study;\n2. Be at least 18 years of age; gender is not a restriction;\n3. Be a patient scheduled to receive treatment with Trastuzumab Rezetecan;\n4. Have an ECOG performance status score of 0-2;\n5. No ascites or pleural effusion requiring drainage;\n6. No gastrointestinal obstruction, such as pyloric stenosis or intestinal obstruction;\n7. Expected survival of ≥12 weeks;\n8. Good organ and bone marrow function, defined as follows:\n\n   Hematologic System (No blood transfusions or treatment with hematopoietic growth factors within the past 14 days)\n   * Absolute Neutrophil Count (ANC) ≥ 1.5×10⁹\u002FL\n   * Platelets (PLT) ≥ 100×10⁹\u002FL\n   * Hemoglobin (Hb) ≥ 90 g\u002FL Liver Function\n   * Total Bilirubin (TBIL) ≤ 1.5×ULN (For patients with Gilbert's syndrome: ≤ 3×ULN)\n   * Alanine Aminotransferase (ALT) ≤ 2.5×ULN (Patients with liver metastases: ≤ 5×ULN)\n   * Aspartate Aminotransferase (AST) ≤ 2.5×ULN (Patients with liver metastases: ≤ 5×ULN)\n   * Albumin (ALB) ≥ 30 g\u002FL Renal Function\n   * Creatinine (Cr) ≤ 1.5×ULN\n   * Creatinine Clearance (Ccr)\n   * (Calculated only when creatinine \\> 1.5×ULN) Endogenous creatinine clearance ≥ 50 mL\u002Fmin (Cockcroft-Gault formula) Cardiac Function\n   * 12-lead electrocardiogram No severe arrhythmias, and a mean Fridericia-corrected QT interval (QTc) of \\\u003C450 ms (males) or \\\u003C470 ms (females)\n   * Echocardiogram Left ventricular ejection fraction (LVEF) ≥ 50%\n9. Agree to cooperate in completing daily nausea and vomiting logs and scale assessments;\n10. Understand the nature of this study; the patient and\u002For legal guardian voluntarily agree to participate in this trial and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Allergy to the study drug or its excipients;\n2. Known contraindications to NK-1 receptor antagonists, 5-HT3 receptor antagonists, or dexamethasone;\n3. Nausea or vomiting at the time of enrollment requiring treatment with antiemetics;\n4. Use of medications with antiemetic effects within 2 days prior to the first dose;\n5. Initiation of potent opioid analgesics within 48 hours prior to enrollment (adjustment of the dose of medications already in use is permitted);\n6. Presence of conditions affecting the assessment of vomiting, such as gastrointestinal obstruction, gastroparesis, or intestinal obstruction;\n7. Patients who are difficult to enroll due to clinically diagnosed psychiatric disorders;\n8. Localized or active systemic infections requiring treatment;\n9. Pregnant or breastfeeding women, as well as patients of childbearing age who refuse to use appropriate contraceptive measures during the course of this trial;\n10. Patients who have participated in other clinical trials within 30 days prior to the first dose of the study drug (patients who failed screening for other clinical trials may be enrolled in this study);\n11. Patients with other factors deemed by the investigator to be unsuitable for participation in this study, such as any physiological or psychological conditions that may increase study risks, affect patient adherence to the protocol, or interfere with the patient's ability to complete the trial.","ALL","18 Years",{"count":19,"type":20},56,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study is a prospective, single-arm, multicenter, exploratory clinical trial divided into a screening phase, a treatment phase, and a follow-up phase. The study aims to evaluate the efficacy and safety of foslorapitant palonosetron for injection in preventing nausea and vomiting caused by treatment with recanituzumab. All patients who meet the inclusion criteria and do not meet any exclusion criteria are eligible for enrollment in this study and are scheduled to receive targeted therapy, antiemetic treatment, and follow-up.\n\nDosage Regimen Eligible subjects will receive a prophylactic antiemetic regimen consisting of foslorapitant and palonosetron.\n\nThe dosage regimen is as follows:\n\nDay 1 (D1): Foslorapitant and palonosetron (218 mg foslorapitant and 0.25 mg palonosetron hydrochloride), administered intravenously (IV) 1 hour prior to chemotherapy.\n\nObserve for two treatment cycles (C1-C2); Starting from the first dose, record the patient's daily vomiting frequency, severity of nausea, and medication adherence.",[26],"Chemotherapy-Induced Nausea and Vomiting (CINV)","RECRUITING","2026-07-22",{"date":30,"type":31},"2026-07-24","ACTUAL",{"date":33,"type":31},"2026-06-15",{"date":35,"type":20},"2028-06-01",{"name":37,"class":38},"Tianjin Medical University Cancer Institute and Hospital","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":4},"100611860","phase-2-nano-crystalline-megestrol-acetate-for-chemotherapy-induced-nausea-and-vomiting-100611860","NCT07246070","Nano-crystalline Megestrol Acetate for Chemotherapy-induced Nausea and Vomiting","The Efficacy and Safety of Nano-crystalline Megestrol Acetate for the Prevention of Nausea and Vomiting Caused by Emetogenic Chemotherapy: a Randomized, Controlled, Multicenter Clinical Study","Inclusion Criteria:\n\n1. Age ≥ 18 years, no gender restrictions;\n2. Histologically or cytologically confirmed locally advanced\u002Frecurrent or metastatic gastric adenocarcinoma that is unresectable for curative treatment;\n3. No prior exposure to any chemotherapy drugs (anticancer drugs not used for cancer treatment, or intravesical instillation therapy for bladder cancer is not considered chemotherapy);\n4. First-line treatment planned to include a moderately emetogenic chemotherapy agent, specifically a PD-1 inhibitor (Tislelizumab is recommended), in combination with the CAPOX chemotherapy regimen for anticancer therapy;\n5. Expected survival ≥ 6 months;\n6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;\n7. Good organ function, meeting the following criteria:\n\n   1. Neutrophil count ≥ 1.5 × 10⁹\u002FL;\n   2. Hemoglobin ≥ 90 g\u002FL;\n   3. Platelet count ≥ 100 × 10⁹\u002FL;\n   4. Total bilirubin ≤ 1.5 × ULN;\n   5. In patients without known liver metastases, aspartate aminotransferase ≤ 2.5 × ULN and\u002For alanine aminotransferase ≤ 2.5 × ULN (for patients with liver metastases, this may be relaxed to ≤ 5 × ULN);\n   6. Serum creatinine ≤ 1.5 × ULN and creatinine clearance ≥ 50 mL\u002Fmin;\n   7. Electrocardiogram: QTc ≤ 450 ms (male), QTc ≤ 470 ms (female);\n   8. Echocardiogram: LVEF (left ventricular ejection fraction) ≥ 50%;\n8. Female participants of childbearing potential, as well as male participants whose partners are of childbearing potential, must use an effective method of contraception from the time of signing the informed consent form until 6 months after the last dose; female participants of childbearing potential must have a negative blood pregnancy test within 72 hours prior to randomization; and must not be breastfeeding;\n9. Clearly understand and voluntarily participate in this study, and sign the informed consent form personally.\n\nExclusion Criteria:\n\n1. Received abdominal (including the diaphragmatic plane and below) or pelvic radiotherapy within 7 days prior to enrollment, or plans to receive such radiotherapy between days 1 and 8 of treatment;\n2. Plans to administer other chemotherapy drugs with moderate to high emetogenic potential between days 2 and 8 following the first day of chemotherapy;\n3. History of venous thromboembolic disease within the past 6 months;\n4. Use of medications with potential antiemetic effects within 2 days prior to enrollment: 5-HT3 receptor antagonists (e.g., ondansetron), phenothiazines (e.g., chlorpromazine), butyrophenones (e.g., haloperidol), benzamides (e.g., metoclopramide), domperidone, cannabinoids, traditional Chinese medicines with potential antiemetic effects, scopolamine, or secobarbital;\n5. Initiation of benzodiazepine or opioid therapy within 2 days prior to enrollment (excluding zolpidem, temazepam, or midazolam taken alone daily);\n6. Initiation of morphine use within 7 days prior to enrollment (excluding those on a stable dose);\n7. Received systemic corticosteroid therapy (including but not limited to dexamethasone, hydrocortisone, methylprednisolone, or prednisolone) or sedating antihistamines (e.g., diphenhydramine) within 7 days prior to enrollment (Note:\n\n   Single-dose corticosteroids for contrast medium allergy prevention, as well as local administration or inhalation, are permitted);\n8. Use of palonosetron within 14 days prior to enrollment;\n9. Use of NK-1 receptor antagonists within 28 days prior to enrollment;\n10. Use of specific CYP3A4 substrates (terfenadine, cisapride, astemizole) or CYP3A4 inhibitors (e.g., ritonavir, clarithromycin, ketoconazole, or itraconazole, diltiazem, etc.), use of strong CYP3A4 inducers (e.g., phenobarbital, rifampin, phenytoin, and carbamazepine) within 28 days prior to enrollment, or use of specific CYP2D6 substrates (e.g., thioridazine, pimozide) within 28 days prior to enrollment;\n11. Vomiting and\u002For nausea within 24 hours prior to enrollment;\n12. Symptomatic brain metastases or any symptoms suggestive of brain metastases or intracranial hypertension;\n13. Uncontrolled serous effusion, including pleural effusion, ascites, or pericardial effusion (patients who have achieved control through treatment and have been stable for ≥2 weeks may be included);\n14. Severe cardiovascular disease within 3 months prior to enrollment, including but not limited to acute myocardial infarction, unstable angina, significant valvular or pericardial disease, history of ventricular tachycardia, symptomatic chronic heart failure (New York Heart Association \\[NYHA\\] Class II to IV), or history of severe cardiac conduction abnormalities (e.g., torsades de pointes);\n15. Uncontrolled hypertension prior to enrollment (two consecutive resting systolic blood pressure readings ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg);\n16. Active hepatitis B (HBV DNA ≥ 2000 IU\u002FmL or 10⁴ copies\u002FmL), active hepatitis C (HCV-Ab positive and HCV-RNA ≥ upper limit of normal), acquired immunodeficiency syndrome (AIDS) or HIV-positive, or syphilis-positive;\n17. Concurrent conditions that preclude the use of dexamethasone, such as active infections (e.g., pneumonia) or any uncontrolled conditions (e.g., diabetic ketoacidosis, gastrointestinal obstruction, etc.);\n18. Known contraindications to NK-1 receptor antagonists, 5-HT3 receptor antagonists, or dexamethasone;\n19. Participation in other clinical trials within 30 days prior to enrollment (as determined by the use of study drugs);\n20. Subjects deemed by the investigator to have other conditions that make them unsuitable for participation in this study.",{"count":48,"type":20},127,[23],"The primary objective of this clinical study is to evaluate the efficacy and safety of nanocrystalline megestrol acetate combined with a 5-HT3 receptor antagonist for the prophylaxis of nausea and vomiting caused by moderately emetogenic chemotherapy drugs.\n\nThe study population consists of gastric adenocarcinoma patients who are scheduled to receive their first course of moderately emetogenic chemotherapy (PD-1\u002FPD-L1 immune checkpoint inhibitors combined with the CAPOX regimen). This study is divided into two phases. The first phase is a single-arm study design, with the primary objective of preliminarily assessing the efficacy and safety of nanocrystalline megestrol acetate combined with a 5-HT3 receptor antagonist for the full-course management of nausea and vomiting caused by moderately emetogenic chemotherapy drugs. The second phase will adopt a randomized, controlled, multicenter trial design. Based on the efficacy and safety data from the first phase, the investigators will optimize the trial design (primarily including the primary endpoint and sample size calculation) to evaluate the efficacy and safety of nanocrystalline megestrol acetate compared with dexamethasone, each combined with a 5-HT3 receptor antagonist, for the prevention of nausea and vomiting caused by moderately emetogenic chemotherapy drugs.",[26],"NOT_YET_RECRUITING","2025-11-20",{"date":55,"type":31},"2025-11-24",{"date":57,"type":20},"2025-12",{"date":59,"type":20},"2026-12",{"name":61,"class":38},"AIPING ZHOU"]